1294512-27-8 Usage
Description
3-(1,1-difluoroallyl)quinoxalin-2-ol is a chemical compound with a quinoxalinone structure, featuring a difluoroallyl group at the 3-position and a hydroxyl group at the 2-position. This molecule is known for its antiviral properties and is also recognized as an intermediate in the synthesis of Glecaprevir (1365970-03-1), a direct-acting antiviral medication used for the treatment of chronic hepatitis C virus (HCV) infection.
Uses
Used in Pharmaceutical Industry:
3-(1,1-difluoroallyl)quinoxalin-2-ol is used as an antiviral agent for its potential to combat viral infections, particularly those caused by hepatitis C virus. Its antiviral activity makes it a valuable compound in the development of treatments for viral diseases.
Additionally, it serves as a crucial intermediate in the synthesis of Glecaprevir, which is used as a direct-acting antiviral drug. This application is significant in the pharmaceutical industry, as it contributes to the production of medications that can effectively manage and treat chronic hepatitis C.
Check Digit Verification of cas no
The CAS Registry Mumber 1294512-27-8 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,9,4,5,1 and 2 respectively; the second part has 2 digits, 2 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 1294512-27:
(9*1)+(8*2)+(7*9)+(6*4)+(5*5)+(4*1)+(3*2)+(2*2)+(1*7)=158
158 % 10 = 8
So 1294512-27-8 is a valid CAS Registry Number.
1294512-27-8Relevant articles and documents
Development of the Enabling Route for Glecaprevir via Ring-Closing Metathesis
Cink, Russell D.,Lukin, Kirill A.,Bishop, Richard D.,Zhao, Gang,Pelc, Matthew J.,Towne, Timothy B.,Gates, Bradley D.,Ravn, Matthew M.,Hill, David R.,Ding, Chen,Cullen, Steven C.,Mei, Jianzhang,Leanna, M. Robert,Henle, Jeremy,Napolitano, José G.,Nere, Nandkishor K.,Chen, Shuang,Sheikh, Ahmad,Kallemeyn, Jeffrey M.
, p. 183 - 200 (2020/02/04)
Glecaprevir was identified as a potent HCV NS3/4A protease inhibitor, and an enabling synthesis was required to support the preclinical evaluation and subsequent Phase I clinical trials. The enabling route to glecaprevir was established through further development of the medicinal chemistry route. The key steps in the synthesis involved a ring-closing metathesis (RCM) reaction to form the 18-membered macrocycle and a challenging fluorination step to form a key amino acid. The enabling route was successfully used to produce 41 kg of glecaprevir, sufficient to support the preclinical evaluation and early clinical development.
Macrocyclic proline derived HCV serine protease inhibitors
-
, (2016/01/20)
The present invention discloses compounds of Formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the com
